Evidence map›Paper›PMID 26038891›Full record

ArticlePloS one2015

Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.

Yayoi Yoshimura, Akihiko Shiino, Kazue Muraki, Tadateru Fukami, Shigeki Yamada, Takeshi Satow, Miyuki Fukuda, Masaaki Saiki, Masato Hojo, Susumu Miyamoto and 5 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Arsenic trioxide as a novel anti-glioma drug: a review.Cellular & molecular biology letters · 2020
    Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Yayoi YoshimuraResearch Institute, Shiga Medical Center, Moriyama 5-4-30, Shiga 524-8524, Japan; Department of Neurosurgery, Shiga University of Medical Science, Shiga 520-2192, Japan.
Akihiko ShiinoBiomedical MR Science Center, Shiga University of Medical Science, Shiga 520-2192, Japan; Department of Neurosurgery, Shiga University of Medical Science, Shiga 520-2192, Japan.
Kazue MurakiResearch Institute, Shiga Medical Center, Moriyama 5-4-30, Shiga 524-8524, Japan.
Tadateru FukamiDepartment of Neurosurgery, Shiga University of Medical Science, Shiga 520-2192, Japan.
Shigeki YamadaDepartment of Neurosurgery, Shiga Medical Center, Shiga 524-8524, Japan.
Takeshi SatowDepartment of Neurosurgery, Shiga Medical Center, Shiga 524-8524, Japan.
Miyuki FukudaDepartment of Neurosurgery, Shiga Medical Center, Shiga 524-8524, Japan.
Masaaki SaikiDepartment of Neurosurgery, Shiga Medical Center, Shiga 524-8524, Japan.
Masato HojoDepartment of Neurosurgery, Shiga Medical Center, Shiga 524-8524, Japan.
Susumu MiyamotoDepartment of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Nobuyuki OnishiDivision of Gene Regulation, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Hideyuki SayaDivision of Gene Regulation, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Toshiro InubushiBiomedical MR Science Center, Shiga University of Medical Science, Shiga 520-2192, Japan.
Kazuhiko NozakiDepartment of Neurosurgery, Shiga University of Medical Science, Shiga 520-2192, Japan.
Kenji TanigakiResearch Institute, Shiga Medical Center, Moriyama 5-4-30, Shiga 524-8524, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is associated with high mortality due to infiltrative growth and recurrence. Median survival of the patients is less than 15 months, increasing requirements for new therapies. We found that both arsenic trioxide and 10058F4, an inhibitor of Myc, induced differentiation of cancer stem-like cells (CSC) of GBM and that arsenic trioxide drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects. EGFR-driven genetically engineered GBM mouse model showed that this cooperative effect is higher in EGFRvIII-expressing INK4a/Arf-/- neural stem cells (NSCs) than in control wild type NSCs. In addition, treatment of GBM CSC xenografts with arsenic trioxide and 10058F4 resulted in significant decrease in tumor growth and increased differentiation with concomitant decrease of proneural and mesenchymal GBM CSCs in vivo. Our study was the first to evaluate arsenic trioxide and 10058F4 interaction in GBM CSC differentiation and to assess new opportunities for arsenic trioxide and 10058F4 combination as a promising approach for future differentiation therapy of GBM.

Indexed as

AgedAnimalsAntineoplastic AgentsApoptosisArsenicalsArsenic TrioxideBrain NeoplasmsCell DifferentiationCell ProliferationDisease ProgressionErbB ReceptorsFemaleGlioblastomaHedgehog ProteinsHumansMagnetic Resonance Imaging5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-oneAntineoplastic AgentsArsenicalsArsenic TrioxideErbB ReceptorsHedgehog ProteinsOxidesProto-Oncogene Proteins c-mycSHH protein, humanThiazoles

Identifiers

PMID26038891
PMCPMC4454553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.